Audentes Therapeutics Initiated Overweight At Wedbush
August 15, 2016 at 08:34 AM EDT
Wedbush has started coverage of Audentes Therapeutics Inc (NASDAQ: BOLD) with an Outperform rating and $20 price target, citing the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.